Erasca (ERAS) Total Liabilities (2020 - 2026)
Erasca posted quarterly Total Liabilities of $67.7 million for Q1 2026, down 5.63% year-on-year from $71.7 million in Q1 2025, and down 4.62% on a QoQ basis from $71.0 million in Q4 2025.
Erasca (ERAS) has 7 years of Total Liabilities data on file, last reported at $67.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities fell 5.63% year-over-year to $67.7 million; the trailing twelve-month figure through Mar 2026 stood at $67.7 million (down 5.63% YoY), and the FY2025 full-year result was $71.0 million, down 10.18% from the prior year.
- Total Liabilities for Q1 2026 stood at $67.7 million, down from $71.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $103.1 million in Q4 2022 and bottomed at $49.8 million in Q2 2022.
- The 5-year median for Total Liabilities is $78.0 million (2023), against an average of $74.9 million.
- Peak annual rise in Total Liabilities reached 154.09% in 2022, while the deepest fall reached 60.69% in 2022.
- A 5-year view of Total Liabilities shows it stood at $103.1 million in 2022, then decreased by 23.72% to $78.6 million in 2023, then rose by 0.53% to $79.0 million in 2024, then dropped by 10.18% to $71.0 million in 2025, then retreated by 4.62% to $67.7 million in 2026.
- The last three Total Liabilities figures came in at $67.7 million (Q1 2026), $71.0 million (Q4 2025), and $72.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 67.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.71 Mn |
| Dec 31, 2025 | 70.98 Mn |
| Sep 30, 2025 | 72.52 Mn |
| Jun 30, 2025 | 73.13 Mn |
| Mar 31, 2025 | 71.74 Mn |
| Dec 31, 2024 | 79.03 Mn |
| Sep 30, 2024 | 78.85 Mn |
| Jun 30, 2024 | 74.66 Mn |
| Mar 31, 2024 | 81.61 Mn |
| Dec 31, 2023 | 78.61 Mn |
| Sep 30, 2023 | 80.43 Mn |
| Jun 30, 2023 | 77.96 Mn |
| Mar 31, 2023 | 81.09 Mn |
| Dec 31, 2022 | 103.06 Mn |
| Sep 30, 2022 | 81.11 Mn |
| Jun 30, 2022 | 49.76 Mn |
| Mar 31, 2022 | 50.81 Mn |
| Dec 31, 2021 | 44.89 Mn |
| Sep 30, 2021 | 38.96 Mn |
| Jun 30, 2021 | 19.58 Mn |
| Mar 31, 2021 | 129.26 Mn |
| Dec 31, 2020 | 17.40 Mn |
| Sep 30, 2020 | 52.82 Mn |
| Jun 30, 2020 | 42.55 Mn |